Your session is about to expire
← Back to Search
Study Summary
This trial is testing a new drug to see if it can reduce blood Phe levels in people with phenylketonuria.
- Phenylketonuria
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2023 Phase 3 trial • 157 Patients • NCT05099640Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
How many people are eligible to partake in this research?
"A total of 178 patients that meet the study's inclusion criteria are required in order to carry out the clinical trial. The sponsor, PTC Therapeutics, will be administering the trial at various sites including The Children's Hospital of Philadelphia in Philadelphia, Pennsylvania and Medical College of Wisconsin in Milwaukee, Wisconsin."
Are there short or long-term risks associated with PTC923?
"PTC923 is in Phase 3 of clinical trials, which puts its safety at a 3."
How many different sites are responsible for conducting this trial?
"Currently, there are 14 different hospitals participating in this study. 3 of these locations are The Children's Hospital of Philadelphia in Philadelphia, Medical College of Wisconsin in Milwaukee, and UF College of Medicine, Department of Pediatrics Division of Genetics and Metabolism in Gainesville. The other 11 locations are _____, _____, _____, _____, _____, _____, _____, _____, _____, _____, _____."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger